Advertisement

Current Treatment Options in Rheumatology

, Volume 4, Issue 1, pp 119–132 | Cite as

IgA Vasculitis in Adults

  • Sarah M. Moran
  • Heather N. Reich
Vasculitis (C Pagnoux and M Walsh, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Vasculitis

Abstract

Purpose of review

Immunoglobulin A vasculitis (IgAV) is a small vessel vasculitis with skin, joint, gastrointestinal and renal manifestations. Our understanding of the natural history of this disease is limited due to the overall low incidence of IgAV in adults and a lack of consensus regarding diagnostic criteria. In this review, we describe IgAV in the adult population, focusing on diagnostic and classification systems, and treatments strategies.

Recent findings

Recent data from larger longitudinal adult cohorts demonstrate that IgAV is associated with significant morbidity and mortality. Treatment regimen remains controversial but emerging retrospective observational data support potential benefit of immunosuppression. As illustrated in trials of IgA nephropathy, immunosuppression carries significant risks of toxicity.

Summary

Treatment regimen and selection of patients who will benefit from treatment remains challenging. Prospective treatment trials are needed to elucidate both the patient populations that will derive benefit and what treatment is most efficacious.

Keywords

IgA vasculitis Henoch-Schonlein purpura Rituximab Vasculitis IgA Nephropathy 

Notes

Acknowledgements

Dr. Moran’s work at the University Health Network is supported by a fellowship from Louise A. Fast and the Fast Foundation.

Compliance with Ethical Standards

Conflict of Interest

Sarah Moran declares that she has no conflict of interest.

Heather N. Reich declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Recently published papers of particular interest have been highlighted as: •• Of major importance

  1. 1.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.  https://doi.org/10.1002/art.37715.
  2. 2.
    Rai A, Nast C, Adler S. Henoch-Schonlein purpura nephritis. J Am Soc Nephrol. 1999;10(12):2637–44.PubMedGoogle Scholar
  3. 3.
    Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch-Schonlein): current state of knowledge. Curr Opin Rheumatol. 2013;25(2):171–8.  https://doi.org/10.1097/BOR.0b013e32835d8e2a.CrossRefPubMedGoogle Scholar
  4. 4.
    Nielsen HE. Epidemiology of Schonlein-Henoch purpura. Acta Paediatr Scand. 1988;77(1):125–31.  https://doi.org/10.1111/j.1651-2227.1988.tb10610.x.CrossRefPubMedGoogle Scholar
  5. 5.
    Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schonlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002;13(5):1271–8.  https://doi.org/10.1097/01.ASN.0000013883.99976.22.CrossRefPubMedGoogle Scholar
  6. 6.
    Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum. 1990;33(8):1114–21.Google Scholar
  7. 7.
    Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798–806.  https://doi.org/10.1136/ard.2009.116657.
  8. 8.
    •• Hocevar A, Rotar Z, Jurcic V, Pizem J, Cucnik S, Vizjak A, et al. IgA vasculitis in adults: the performance of the EULAR/PRINTO/PRES classification criteria in adults. Arthritis Res Ther. 2016;18:58. This study provides a validation of and comparison between classification systems of IgAV in the adult population.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, et al. ACR/EULAR-endorsed study to develop diagnostic and classification criteria for Vasculitis (DCVAS). Clin Exp Nephrol. 2013;17(5):619–21.  https://doi.org/10.1007/s10157-013-0854-0.
  10. 10.
    •• Audemard-Verger A, Terrier B, Dechartres A, Chanal J, Amoura Z, Le Gouellec N, et al. Characteristics and management of IgA vasculitis (Henoch-Schonlein) in adults: data from 260 patients Included in a French Multicenter Retrospective Survey. Arthritis Rheumatol. 2017;69(9):1862–70. This is the largest observational study in IgAV and provides information on clinical presentation, treatments used and outcomes.Google Scholar
  11. 11.
    Tancrede-Bohin E, Ochonisky S, Vignon-Pennamen MD, Flageul B, Morel P, Rybojad M. Schonlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch Dermatol. 1997;133(4):438–42.  https://doi.org/10.1001/archderm.1997.03890400034005.CrossRefPubMedGoogle Scholar
  12. 12.
    Nadrous HF, Yu AC, Specks U, Ryu JH. Pulmonary involvement in Henoch-Schonlein purpura. Mayo Clin Proc. 2004;79(9):1151–7.  https://doi.org/10.4065/79.9.1151.PubMedGoogle Scholar
  13. 13.
    Rajagopala S, Shobha V, Devaraj U, D'Souza G, Garg I. Pulmonary hemorrhage in Henoch-Schonlein purpura: case report and systematic review of the English literature. Semin Arthritis Rheum. 2013;42(4):391–400.  https://doi.org/10.1016/j.semarthrit.2012.07.004.CrossRefPubMedGoogle Scholar
  14. 14.
    Garcia-Porrua C, Gonzalez-Gay MA. Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schonlein purpura in adults. Semin Arthritis Rheum. 1999;28(6):404–12.  https://doi.org/10.1016/S0049-0172(99)80006-7.CrossRefPubMedGoogle Scholar
  15. 15.
    Maestri A, Malacarne P, Santini A. Henoch-Schonlein syndrome associated with breast cancer. A case report. Angiology. 1995;46(7):625–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Cream JJ, Gumpel JM, Peachey RD. Schonlein-Henoch purpura in the adult. A study of 77 adults with anaphylactoid or Schonlein-Henoch purpura. Q J Med. 1970;39(156):461–84.PubMedGoogle Scholar
  17. 17.
    Pertuiset E, Liote F, Launay-Russ E, Kemiche F, Cerf-Payrastre I, Chesneau AM. Adult Henoch-Schonlein purpura associated with malignancy. Semin Arthritis Rheum. 2000;29(6):360–7.  https://doi.org/10.1053/sarh.2000.6988.CrossRefPubMedGoogle Scholar
  18. 18.
    Pankhurst T, Lepenies J, Nightingale P, Howie AJ, Adu D, Harper L. Vasculitic IgA nephropathy: prognosis and outcome. Nephron Clin Pract. 2009;112(1):c16–24.  https://doi.org/10.1159/000210570.CrossRefPubMedGoogle Scholar
  19. 19.
    Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–56.  https://doi.org/10.1038/ki.2009.168.CrossRefPubMedGoogle Scholar
  20. 20.
    Haas M, Verhave JC, Liu ZH, Alpers CE, Barratt J, Becker JU et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017;28(2):691–701.  https://doi.org/10.1681/ASN.2016040433.CrossRefPubMedGoogle Scholar
  21. 21.
    Exley AR, Bacon PA. Clinical disease activity in systemic vasculitis. Curr Opin Rheumatol. 1996;8(1):12–8.  https://doi.org/10.1097/00002281-199601000-00002.CrossRefPubMedGoogle Scholar
  22. 22.
    Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605–17.  https://doi.org/10.1136/ard.2006.062711.CrossRefPubMedGoogle Scholar
  23. 23.
    Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69(6):1036–43.  https://doi.org/10.1136/ard.2009.109389.
  24. 24.
    Kato S, Ebina K, Naganuma H, Sato S, Maisawa S, Nakagawa H. Intestinal IgA deposition in Henoch-Schonlein purpura with severe gastro-intestinal manifestations. Eur J Pediatr. 1996;155(2):91–5.  https://doi.org/10.1007/BF02075757.CrossRefPubMedGoogle Scholar
  25. 25.
    Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119(6):1668–77.  https://doi.org/10.1172/JCI38468.
  26. 26.
    Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest. 2014;124(6):2325–32.  https://doi.org/10.1172/JCI74475.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26(7):1503–12.  https://doi.org/10.1681/ASN.2014101000.
  28. 28.
    Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney Int. 2011;80(1):79–87.  https://doi.org/10.1038/ki.2011.16.
  29. 29.
    Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22(4):752–61.  https://doi.org/10.1681/ASN.2010040355.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mohey H, Laurent B, Mariat C, Berthoux F. Validation of the absolute renal risk of dialysis/death in adults with IgA nephropathy secondary to Henoch-Schonlein purpura: a monocentric cohort study. BMC Nephrol. 2013;14(1):169.  https://doi.org/10.1186/1471-2369-14-169.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, et al. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney Int. 2017;92(2):461–9.  https://doi.org/10.1016/j.kint.2017.03.015.
  32. 32.
    Hocevar A, Rotar Z, Keizar N, Tomsic M. A model predicting short term severity of IgA vasculitis in adults. J Clin Exp Dermatol Res. 2017;8:397.CrossRefGoogle Scholar
  33. 33.
    KDIGO Clinical Practice Guideline for Glomerulonephritis: National Kidney Foundation. 2012.Google Scholar
  34. 34.
    Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schonlein purpura (HSP). Cochrane Database Syst Rev. 2009;3:CD005128.Google Scholar
  35. 35.
    Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432–42.  https://doi.org/10.1001/jama.2017.9362.
  36. 36.
    Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36.  https://doi.org/10.1056/NEJMoa1415463.
  37. 37.
    Augusto JF, Sayegh J, Delapierre L, Croue A, Tollis F, Cousin M, et al. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schonlein purpura in adults: a case series. Am J kidney Dis. 2012;59(5):663–9.  https://doi.org/10.1053/j.ajkd.2011.12.015.
  38. 38.
    Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apher. 2016;31(3):149–62.  https://doi.org/10.1002/jca.21470.
  39. 39.
    Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E, group Cs. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein Purpura. Kidney Int. 2010;78(5):495–502.CrossRefPubMedGoogle Scholar
  40. 40.
    Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener’s granulomatosis. J Allergy Clin Immunol. 1999;103(5 Pt 1):885–94.  https://doi.org/10.1016/S0091-6749(99)70434-3.CrossRefPubMedGoogle Scholar
  41. 41.
    •• Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306–1313.  https://doi.org/10.1681/ASN.2016060640. In this randomized controlled trial of patients with IgAN, rituximab therapy did not result in improvent in renal function or proteinuria at one year.
  42. 42.
    Floege J. Glomerular disease: rituximab therapy for IgA nephropathy. Nat Rev Nephrol. 2017;13(3):138–40.  https://doi.org/10.1038/nrneph.2016.188.CrossRefPubMedGoogle Scholar
  43. 43.
    Pillebout E, Rocha F, Fardet L, Rybojad M, Verine J, Glotz D. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044–6.  https://doi.org/10.1093/ndt/gfr137.CrossRefPubMedGoogle Scholar
  44. 44.
    Lundberg S, Westergren E, Smolander J, Bruchfeld A. B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017;10(1):20–6.  https://doi.org/10.1093/ckj/sfw106.PubMedGoogle Scholar
  45. 45.
    Fenoglio R, Naretto C, Basolo B, Quattrocchio G, Ferro M, Mesiano P, et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res. 2017;65(1):186–92.  https://doi.org/10.1007/s12026-016-8827-5.
  46. 46.
    •• Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R et al. Brief report: Rituximab for the treatment of adult-onset vasculitis. 2018;70(1):109-14. A retrospective case series of 22 patients with IgA treated with Rituximab with two years of follow-up.Google Scholar
  47. 47.
    Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Kim PK, et al. Can azathioprine and steroids alter the progression of severe Henoch-Schonlein nephritis in children? Pediatr Nephrol. 2005;20(8):1087–92.  https://doi.org/10.1007/s00467-005-1869-x.
  48. 48.
    Fotis L, Tuttle PV, Baszis KW, Pepmueller PH, Moore TL, White AJ. Azathioprine therapy for steroid-resistant Henoch-Schonlein purpura: a report of 6 cases. Pediatr Rheumatol Online J. 2016;14:37.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–8.  https://doi.org/10.1001/jama.2010.1658.
  50. 50.
    Ren P, Han F, Chen L, Xu Y, Wang Y, Chen J. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schonlein purpura nephritis. Am J Nephrol. 2012;36(3):271–7.  https://doi.org/10.1159/000341914.CrossRefPubMedGoogle Scholar
  51. 51.
    Du Y, Hou L, Zhao C, Han M, Wu Y. Treatment of children with Henoch-Schonlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol. 2012;27(5):765–71.  https://doi.org/10.1007/s00467-011-2057-9.CrossRefPubMedGoogle Scholar
  52. 52.
    Ehrenfeld M, Levy M, Bar Eli M, Gallily R, Eliakim M. Effect of colchicine on polymorphonuclear leucocyte chemotaxis in human volunteers. Br J Clin Pharmacol. 1980;10(3):297–300.  https://doi.org/10.1111/j.1365-2125.1980.tb01759.x.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Levy M, Ehrenfeld M, Gallily R, Eliakim M. Enhanced polymorphonuclear chemotaxis—a common feature of diseases responsive to colchicine. Med Hypotheses. 1981;7(1):15–20.  https://doi.org/10.1016/0306-9877(81)90017-7.CrossRefPubMedGoogle Scholar
  54. 54.
    Pyne D, Mootoo R, Bhanji A. Colchicine for the treatment of recurrent Henoch-Schonlein purpura in an adult. Rheumatology (Oxford). 2001;40(12):1430–1.  https://doi.org/10.1093/rheumatology/40.12.1430.CrossRefGoogle Scholar
  55. 55.
    Oortwijn BD, Eijgenraam JW, Rastaldi MP, Roos A, Daha MR, van Kooten C. The role of secretory IgA and complement in IgA nephropathy. Semin Nephrol. 2008;28(1):58–65.  https://doi.org/10.1016/j.semnephrol.2007.10.007.CrossRefPubMedGoogle Scholar
  56. 56.
    Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17(6):1724–34.  https://doi.org/10.1681/ASN.2005090923.
  57. 57.
    Espinosa M, Ortega R, Sanchez M, Segarra A, Salcedo MT, Gonzalez F, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol: CJASN. 2014;9(5):897–904.  https://doi.org/10.2215/CJN.09710913.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sarah M. Moran
    • 1
    • 2
    • 3
  • Heather N. Reich
    • 1
    • 2
    • 4
  1. 1.The Toronto Glomerulonephritis Registry and Division of NephrologyUniversity Health NetworkTorontoCanada
  2. 2.Department of MedicineUniversity of TorontoTorontoCanada
  3. 3.Trinity Health Kidney Centre, Trinity College DublinDublinIreland
  4. 4.Gabor Zellerman Chair in Nephrology ResearchTorontoCanada

Personalised recommendations